Bio-Rad Laboratories (NYSE:BIO.B) Shares Gap Up - What's Next?

Key Points

• Bio-Rad Laboratories shares opened at $283.85, significantly above the previous close of $247.05, reflecting a rise of 15.3%.
• The company's market capitalization stands at $7.75 billion, with a price-to-earnings ratio of 24.29 and a net margin of 12.50%.
• Bio-Rad reported $651.60 million in revenue for the last quarter, with earnings per share of $2.61.

Bio-Rad Laboratories, Inc. (NYSE:BIO.B - Get Free Report) gapped up prior to trading on Friday . The stock had previously closed at $247.05, but opened at $283.85. Bio-Rad Laboratories shares last traded at $284.88, with a volume of 300 shares.

Bio-Rad Laboratories Stock Up 15.3%

The firm has a market capitalization of $7.75 billion, a price-to-earnings ratio of 24.29 and a beta of 0.81. The company's 50 day moving average price is $259.94 and its 200 day moving average price is $250.50. The company has a quick ratio of 3.67, a current ratio of 5.12 and a debt-to-equity ratio of 0.17.

Bio-Rad Laboratories (NYSE:BIO.B - Get Free Report) last posted its earnings results on Thursday, July 31st. The company reported $2.61 earnings per share (EPS) for the quarter. Bio-Rad Laboratories had a net margin of 12.50% and a return on equity of 4.01%. The company had revenue of $651.60 million during the quarter.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.